CAMP4 Therapeutics wins MHRA nod for CMP-002 SYNGAP1 Phase 1/2 trial
CAMP4 Therapeutics has received authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to enrol patients at British sites in its ongoing global Phase 1/2 clinical trial of CMP-002, the company's lead antisense oligonucleotide (ASO) candidate for SYNGAP1-related disorder. The Watertown, Massachusetts-based biotech expects to initiate the study in the fourth quarter of 2026.
The UK clearance follows regulatory green lights granted in July 2026 by Australia's Therapeutic Goods Administration and Argentina's ANMAT. CAMP4 has also filed for authorisation in the European Union, where submissions remain under review. The simultaneous multi-jurisdiction strategy is intended to accelerate enrolment in what is a small and geographically dispersed patient population.
The candidate and its mechanism
CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA, boosting expression of the SYNGAP1 gene and nudging SYNGAP protein levels back toward wild-type. The drug is administered intrathecally. In preclinical work, the company says it demonstrated dose-dependent protein upregulation in patient-derived neurons, reversal of behavioural phenotypes in a humanised haploinsufficient mouse model, and statistically significant improvement in seizure parameters in a chemically induced seizure model. Broad brain distribution with measurable SYNGAP protein upregulation was also reported in non-human primates.
SYNGAP1-related disorder is a rare, haploinsufficient CNS condition caused by mutations in the SYNGAP1 gene that leave patients with roughly half the normal complement of SYNGAP protein. The condition is estimated to affect more than 10,000 individuals in the United States alone. Intellectual disability is present in all diagnosed patients; epilepsy affects approximately 85%; severe behavioural problems arise in about 70%; and around 30% of patients are non-verbal. No disease-modifying therapy is currently approved for the condition.
Josh Mandel-Brehm, president and chief executive of CAMP4, said the MHRA authorisation "expands the reach of our Phase 1/2 clinical trial and reinforces our commitment to rapidly advancing CMP-002 for patients and their families who have been without an intervention that tackles the underlying drivers of this disease."
Market context and competitive landscape
The rare CNS genetic disease space has seen growing interest from biotech and large pharma alike, driven partly by the maturation of ASO technology and improvements in intrathecal delivery. Ionis Pharmaceuticals and its partners have established several precedents for intrathecally administered ASOs in CNS indications, most notably nusinersen in spinal muscular atrophy, which has shaped regulatory expectations around this delivery route at both the FDA and EMA. That precedent is broadly favourable for developers targeting haploinsufficient neurological disorders with similar modalities.
CAMP4's RAP Platform, which maps regulatory RNAs to identify targets for gene upregulation, is positioned as a platform approach rather than a single-asset play. The company cites more than 1,200 haploinsufficient and recessive partial loss-of-function disorders as theoretically addressable. Whether that platform breadth translates into partnering interest or additional pipeline candidates will be a key question for investors as the CMP-002 trial opens. Near-term catalysts include confirmation of Q4 2026 trial initiation, EU regulatory clearance, and early Phase 1 safety data expected in 2027.